Acetylcholinesterase (AChE) inhibitors show good therapeutic effects on myasthenia gravis, glaucoma, and Alzheimer's disease through reversible enzyme inhibition so as to increase the accumulation of acetylcholine in the synapse and then promote and prolong the function of acetylcholine. The gene discussed is ACHE; the disease is glaucoma.